Office of Technology Transfer – University of Michigan

Omega-3 Fatty Acid Metabolite Compositions and Methods of Use Thereof for Treatment and Prevention of Gastrointestinal Disorders and Visceral Hypersensitivity

Technology #7520

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Researchers
Chung Owyang
Managed By
Stefan Koehler
Patent Protection
US Patent Pending

Irritable bowel syndrome (IBS) is an intestinal inflammatory disorder affecting 14.1% of the United States. Symptoms include abdominal pain, changes in the pattern of bowel movement and also impacts quality of life with psychological impacts including anxiety, major depression, and chronic fatigue syndrome. Introduction of probiotics has been shown to reduce symptoms of IBS, however no molecular basis for the benefits of probiotics has been elucidated.

Molecular Probiotic Interventions for the Treatment of IBS

One secreted soluble protein and one small molecule metabolite have been identified to combat visceral hypersensitivity & inflammation in IBS via restoration of gut permeability, and additionally restoring levels of anti-inflammatory molecules respectfully. Recombinant protein was shown to restore the permeability in human colonoids and restore the homeostasis of epigenetic proteins/markers.

Applications

  • Therapeutics for the treatment of irritable bowel syndrome
  • Therapeutics for other inflammatory gastrointestinal diseases
  • Diagnostic for IBS/gastrointestinal diseases

Advantages

  • Both treatments originate from probiotics that have been shown to have favorable efficacy for patients with IBS
  • Favorable efficacy in-vitro
  • Can be obtained in high quantities